Mark Joshua Kayton

US Patent:

6734168, May 11, 2004

Filed:

May 7, 2001

Appl. No.:

09/851026

Inventors:

David M. Stern - Great Neck NY
Matthias Clauss - Bad Nauheim, DE
Janet Kao - New York NY
Mark Kayton - New York NY
Steven K. Libutti - Fort Lee NJ

Assignee:

The Trustees of Columbia University in the City of New York - New York NY

International Classification:

A61K 3800

US Classification:

514 12, 514 13

Abstract:

The present invention provides for a purified endothelial monocyte activating polypeptide II, wherein the polypeptide has an apparent molecular weight of about 20,000 Daltons. The present invention also provides for an effector cell activating protein comprising a polypeptide having an amino acid sequence wherein at least four amino acid residues are the same as RIGRTVT and are in the same relative positions. The invention also provides for a DNA which encodes the effector cell activating protein. The invention also provides for methods of inducing inflammation in a subject and methods of treating tumors in a subject. The invention also provides for a pharmaceutical composition which comprises the endothelial monocyte activating polypeptide II and a carrier.

US Patent:

20050136006, Jun 23, 2005

Filed:

Dec 16, 2004

Appl. No.:

11/014472

Inventors:

Steven Libutti - North Potomac MD, US
Mark Kayton - New York NY, US

Assignee:

Government of the U.S.A.,represented by the Secretary, Department of Health & Human Services - Rockville MD

International Classification:

A61K049/00
G06F019/00
G01N033/48
G01N033/50
G06K009/00

US Classification:

424009200, 702019000, 382128000

Abstract:

A method of measuring the angiogenic or antiangiogenic activity of a test molecule comprising (i) utilizing a modified CAM assay to assign an FVD value for a test region of interest and comparing this value to an FVD value for a control region of interest, or (ii) utilizing a modified CAM assay to determine the spectrophotometric absorbance value of a test region of interest and comparing this value to the spectrophotometric absorbance value of a control region of interest, wherein a lower value of the test region of interest as compared to the of the control region of interest is indicative of the test molecule being useful as an inhibitor of angiogenesis, and wherein a higher value of the test region of interest as compared to the value of the control region of interest is indicative of the test molecule being useful as a stimulator of angiogenesis. Furthermore, such measurements of angiogenic or antiangiogenic activity may be monitored in an animal or patient afflicted with a disease.

US Patent:

20050175980, Aug 11, 2005

Filed:

Apr 9, 2003

Appl. No.:

10/510652

Inventors:

Steven Libutti - North Potomac MD, US
Mark Kayton - New York NY, US

Assignee:

Government of the United States of America, repres by the Secretary, Dept. of Health and Human Serv. - Rockville MD

International Classification:

C12Q001/00

US Classification:

435004000

Abstract:

A method of measuring the angiogenic or antiangiogenic activity of a test molecule comprising (i) utilizing a modified CAM assay to assign an FVD value for a test region of interest and comparing this value to an FVD value for a control region of interest, or (ii) utilizing a modified CAM assay to determine the spectrophotometric absorbance value of a test region of interest and comparing this value to the spectrophotometric absorbance value of a control region of interest, wherein a lower value of the test region of interest as compared to the of the control region of interest is indicative of the test molecule being useful as an inhibitor of angiogenesis, and wherein a higher value of the test region of interest as compared to the value of the control region of interest is indicative of the test molecule being useful as a stimulator of angiogenesis.

US Patent:

56418671, Jun 24, 1997

Filed:

Sep 29, 1993

Appl. No.:

8/129456

Inventors:

David M. Stern - Great Neck NY
Matthias Clauss - Bad Nauheim, DE
Janet Kao - New York NY
Mark Kayton - New York NY
Steven K. Libutti - Fort Lee NJ

Assignee:

The Trustees of Columbia University in the City of New York - New York NY

International Classification:

C07K 1624

US Classification:

53038823

Abstract:

This invention provides a purified endothelial monocyte activating polypeptide (EMAP II). It further provides a method of obtaining purified endothelial monocyte activating polypeptide (EMAP II), a method of making antibodies to it and a method of detecting it. This invention also provides an effector cell activating protein which contains an amino acid sequence homologous to RIGRIVT and a method of detecting same. This invention also provides a method of treating a tumor in a subject by administering an effective dose of endothelial monocyte activating polypeptide (EMAP II).

US Patent:

62288377, May 8, 2001

Filed:

Oct 8, 1996

Appl. No.:

8/360821

Inventors:

David M. Stern - Great Neck NY
Matthias Clauss - Bad Nauheim, DE
Janet Kao - New York NY
Mark Kayton - New York NY
Steven K. Libutti - Fort Lee NJ

Assignee:

The Trustees of Columbia University in the City of New York - New York NY

International Classification:

A61K 3800

US Classification:

514 12

Abstract:

This invention provides a purified endothelial monocyte activating polypeptide (EMAP II). It further provides a method of obtaining purified endothelial monocyte activating polypeptide (EMAP II), a method of making antibodies to it and a method of detecting it. This invention also provides an effector cell activating protein which contains an amino acid sequence homologous to RIGRIVT and a method of detecting same. This invention also provides a method of treating a tumor in a subject by administering an effective dose of endothelial monocyte activating polypeptide (EMAP II).